Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Frontline Plc Ordinary Shares (FRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Frontline Plc Ordinary Shares — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15 (market cap $2.81B), while Frontline Plc Ordinary Shares trades at $53.65 (market cap $12.53B). The key difference: Frontline Plc Ordinary Shares is far larger — about 4.5× Dyne Therapeutics Inc. Common Stock's market cap, and Frontline Plc Ordinary Shares pays a 9.56% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Frontline Plc Ordinary Shares for 1 Days on average.
| DYN | FRO | |
|---|---|---|
Market Cap | $2.81B | $12.53B |
Volume | 2,195,902 | 7,205,699 |
Sector | Health | Industrials |
52-Week High | $26.78 | $59.19 |
52-Week Low | $14.60 | $20.58 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $2.13B | $14.64B |
Dividend Yield | — | 9.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Frontline (FRO) trades at $59.04, down 0.25% on the day, but maintains a strong technical and fundamental position. The stock is near its 52-week high, supported by bullish moving averages and robust earnings, with Q2 2026 EPS beating estimates at $2.96. Revenue and profitability have surged, with 2026 net income margin projected at 54.75%. Recent news highlights a special dividend declaration and institutional buying interest.
The outlook for FRO is positive, driven by record earnings and favorable shipping market dynamics. Investment opportunities include strong cash flow generation and shareholder returns, but risks involve exposure to volatile freight rates and geopolitical tensions affecting global trade. Analyst sentiment is mixed, with a 'Hold' consensus suggesting cautious optimism amid near-term highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Frontline Plc Ordinary Shares
Frontline operates a fleet of oil tankers that transport crude oil by sea. Its vessels serve global energy trading routes.
Read more on FRO →
